Pharma Integrates 2022 Track 1
How do we tackle some of the biggest health challenges, such as chronic conditions, respiratory and cancer?
Welcome and opening remarks
Rise of the centenarians
An industry is forming around human longevity to treat age-related diseases and extend our lives. What does this mean for Pharma? How do we tackle age-related diseases like dementia?
Lord James O’Shaughnessy | Senior Partner | Newmarket Strategy
Tina Woods | Founder and CEO | Collider Health
Nick Stephens | Executive Chairman | The RSA Group
Samantha Benham-Hermetz | Director of Policy and Public Affairs | Alzheimer’s Research UK
Giovanna Mallucci | Founding Principal Investigator | Altos Labs
Take a breather
Asthma affects 5.4 million in the UK. Tragically, four people die every day because of asthma attacks. A major study into asthma deaths (the National Review of Asthma Deaths 2014) found that two-thirds of asthma deaths are preventable. Join us for a session that explores the recent technological advances in asthma treatments, the latest research agenda and policies to overcome the burden of this disease.
Tamsin Berry | Head of Policy and Partnerships, AreteiaTx | Partner, Population Health Partners
Jorge Bartolome | Chief Executive Officer | Areteia Therapeutics, Inc
Sarah Woolnough | Chief Executive Officer | Asthma + Lung UK
Salman Siddiqui | Clinical Professor of Respiratory and Experimental Medicine | National Heart and Lung Institute (NHLI), Imperial College
Andrew Roddam | Chief Executive Officer | Our Future Health
Dare to think rare
The advancements in breakthrough therapies, such as cell and gene therapies, over the past few decades has been exponential, but how do we increase access for patients with rare diseases?
Jo Pisani | Strategic Advisor, Non Executive Director and Charity Trustee | The RSA Group
Tauhid Ali | Chief Executive Officer | Oak Hill Bio Ltd
Portia Thorman | Advocacy Lead | Spinal Muscular Atrophy UK
Imran Kausar | VP & General Manager Northern Europe Cluster | Novartis
Roudie Shafie | Director | OVID Health
The Big ‘C’
As Europe’s population gets older, the number of people being diagnosed with cancer could increase by up to 18% in 2040. Advances in prevention, early detection, diagnosis and treatments are improving patient outcomes, but there is still a lot more to do.
Linda Summerton | Head of Scientific Affairs & Oncology | tranScrip
Jason Mellad | Chief Executive Officer | Start Codon
Martino Picardo | Chairman | Discovery Park
Marcel Gehrung | Chief Executive Officer and Co-Founder | Cyted
Renata Crome | Trustee, Non Executive Director and Pharmaceutical Development Advisor | PTEN Research Foundation
Emma Kinloch | Founder | Salivary Gland Cancer UK (SGC UK)
Jane Robertson | Chief Medical Officer | Redx Pharma